In the Literature presents brief summaries of Commonwealth Fundsupported research recently published in professional journals. To read or learn more about new publications as soon as they become available, visit www.cmwf.org and register to receive Commonwealth Fund e-mail alerts. In the article, the researchers trace the rise of drug costs in provincial drug benefit planswhich have approximately doubled since 1995-and the consequent erosion of drug benefits through increased eligibility requirements and user charges.
THE COMMONWEALTH FUND
Even though provincial plans together represent 42 percent of national prescription drug expenditures, the plans generally do not seek to negotiate prices with drug suppliers. A federal Patented Medicine Prices Review Board monitors drug costs by comparing patented drug prices with those in seven other nations. The cap on costs for patented drugs is the median price charged in France, Germany, Italy, Switzerland, the United Kingdom, and the United States. Yet, the authors find, there is no provincial or federal oversight of the costeffectiveness of different drugs, and the price controls have had only minimal effects.
Utilization
All provincial drug plans use a formulary and require some user charges in the form of copayments or deductibles. In addition, British Columbia has implemented reference pricing to encourage the use of cheaper drugs in a therapeutic class. There is evidence that the policy has reduced drug spending in the province without affecting access to high-quality care. Even so, a backlash from the pharmaceutical industry (including successful legal challenges, a public relations campaign, and threats to reduce research spending) has discouraged other provinces from adopting the price control technique.
The authors find that the tension between health needs and industrial policies has hampered effective prescription drug regulation in Canada, and would likely affect policies in the United States and abroad. They conclude that a sustainable pharmaceutical benefit programwhether in Canada or abroad-requires effective pricing and utilization management. Policies must ensure that prices reflect therapeutic value and that patients and prescribers have information and incentives to balance potential benefits and actual costs.
The Canadian experience also suggests that political leadership is needed to ensure that a U.S. Medicare prescription drug benefit includes management systems to control costs. Without such control, the researchers suggest, a Medicare drug benefit would face rising costs and diminishing benefits.
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